Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2011 3
2012 2
2014 2
2016 2
2018 2
2019 1
2020 2
2021 2
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Regulatory T-cell Transcriptomic Reprogramming Characterizes Adverse Events by Checkpoint Inhibitors in Solid Tumors.
Grigoriou M, Banos A, Hatzioannou A, Kloetgen A, Kouzis P, Aggouraki D, Zakopoulou R, Bamias G, Kassi E, Mavroudis D, Bamias A, Boumpas DT, Tsirigos A, Gogas H, Alissafi T, Verginis P. Grigoriou M, et al. Among authors: aggouraki d. Cancer Immunol Res. 2021 Jul;9(7):726-734. doi: 10.1158/2326-6066.CIR-20-0969. Epub 2021 Apr 5. Cancer Immunol Res. 2021. PMID: 33820810 Free PMC article.
Clinical Relevance of Immune Checkpoints on Circulating Tumor Cells in Breast Cancer.
Papadaki MA, Koutsopoulos AV, Tsoulfas PG, Lagoudaki E, Aggouraki D, Monastirioti A, Koutoulaki C, Apostolopoulou CA, Merodoulaki AC, Papadaki C, Mavroudis D, Agelaki S. Papadaki MA, et al. Among authors: aggouraki d. Cancers (Basel). 2020 Feb 6;12(2):376. doi: 10.3390/cancers12020376. Cancers (Basel). 2020. PMID: 32041353 Free PMC article.
TLR4 and pSTAT3 Expression on Circulating Tumor Cells (CTCs) and Immune Cells in the Peripheral Blood of Breast Cancer Patients: Prognostic Implications.
Papadaki MA, Monastirioti A, Apostolopoulou CA, Aggouraki D, Papadaki C, Michaelidou K, Vassilakopoulou M, Alexakou K, Mavroudis D, Agelaki S. Papadaki MA, et al. Among authors: aggouraki d. Cancers (Basel). 2022 Feb 18;14(4):1053. doi: 10.3390/cancers14041053. Cancers (Basel). 2022. PMID: 35205801 Free PMC article.
Evaluation of PD-L1/PD-1 on circulating tumor cells in patients with advanced non-small cell lung cancer.
Kallergi G, Vetsika EK, Aggouraki D, Lagoudaki E, Koutsopoulos A, Koinis F, Katsarlinos P, Trypaki M, Messaritakis I, Stournaras C, Georgoulias V, Kotsakis A. Kallergi G, et al. Among authors: aggouraki d. Ther Adv Med Oncol. 2018 Jan 15;10:1758834017750121. doi: 10.1177/1758834017750121. eCollection 2018. Ther Adv Med Oncol. 2018. PMID: 29383038 Free PMC article.
CD8+ PD-1+ T-cells and PD-L1+ circulating tumor cells in chemotherapy-naïve non-small cell lung cancer: towards their clinical relevance?
Kotsakis A, Kallergi G, Aggouraki D, Lyristi Z, Koinis F, Lagoudaki E, Koutsopoulos A, Georgoulias V, Vetsika EK. Kotsakis A, et al. Among authors: aggouraki d. Ther Adv Med Oncol. 2019 Jun 12;11:1758835919853193. doi: 10.1177/1758835919853193. eCollection 2019. Ther Adv Med Oncol. 2019. PMID: 31217824 Free PMC article.
Optimization of the Enrichment of Circulating Tumor Cells for Downstream Phenotypic Analysis in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-1 Immunotherapy.
Papadaki MA, Sotiriou AI, Vasilopoulou C, Filika M, Aggouraki D, Tsoulfas PG, Apostolopoulou CA, Rounis K, Mavroudis D, Agelaki S. Papadaki MA, et al. Among authors: aggouraki d. Cancers (Basel). 2020 Jun 12;12(6):1556. doi: 10.3390/cancers12061556. Cancers (Basel). 2020. PMID: 32545559 Free PMC article.
16 results